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Abstract
Aims: To study the effect of the recombinant human bone morphogenetic protein 2 (rhBMP-2) on
sinus volumetric and histometric changes after sinus floor augmentation compared to a
conventional approach of non-biologic bone grafting materials.
Materials and methods: An electronic search of 4 databases (January 1990–February 2015),
including PubMed/MEDLINE, EMBASE, Web of Science and Cochrane Central, and a hand search of
peer-reviewed journals for relevant articles were performed. Human clinical trials with data on
comparison of sinus volumetric and/or histometric outcomes with and without the use of rhBMP-2
in sinus grafting procedures, with ≥10 augmentation sites in each study group, and with a follow-
up period of at least 6 months, were included. Random-effects meta-analyses were performed to
analyze weighted mean difference (WMD) and confidence interval (CI) for the recorded variables
according to PRISMA guidelines.
Results: Six randomized controlled trials (RCTs) were included. The results of the meta-analyses
showed that the WMD of vertical bone height gain was 0.14 mm (95% CI = 1.91 to 1.62 mm,
P = 0.87), the WMD of bone density was 142.42 mg/cm3 (95% CI = 310.62–25.78 mg/cm3,
P = 0.10), the WMD of the percentage of vital bone was 4.59% (95% CI = 11.73–2.56%,
P = 0.21), and the WMD of the percentage of residual bone grafting materials was 9.90% (95%
CI = 26.38–6.58%, P = 0.21). The comparison of implant survival rate presented an overall risk
ratio of 1.00 (95% CI = 0.94–1.07). The two approaches (conventional bone grafting compared to
BMPs) demonstrated comparable effectiveness for both clinical and histomorphometric measures.
Conclusions: This systematic review revealed that the use of rhBMP-2 in maxillary sinus floor
augmentation achieved similar clinical and histometric outcomes when compared to conventional
sinus grafting procedures after a healing period of 6–9 months. However, previous studies showed
the morbidity and other patient-reported outcomes were improved in rhBMP-2 approaches as
compared to bone autograft procedures (both intraoral and extraoral bone harvesting because no
donor site is required). Long-term studies are required to determine the cost-benefit of sinus floor
augmentation procedures for patients requiring implant reconstruction.
Introduction
Bone formation, maintenance, and regenera-
tion involve a cascade of complex cellular
interactions in the signaling pathway. Bone
morphogenetic proteins (BMPs) are a group of
naturally formed multifunctional growth
actors found in human body and are part of
the transforming growth factor b (TGF-b)
superfamily. BMPs initiate the signaling
pathway by binding to specific serine–thre-
onine kinase cell surface receptors that phos-
phorylate and activate the downstream
cascade of intracellular proteins interactions.
Ultimately, the intracellular proteins
promote gene expression by forming several
regulatory complexes and bind to the pro-
moter regions of target genes in the nucleus.
BMPs, including BMP-2, are involved in
several critical pathways that influence
osteoblastogenesis and bone formation: Smad
pathway, Hedgehog pathway, TGF-b path-
way, and cytokine–cytokine receptor interac-
tion (Fig. 1). BMP-2 target genes include a
wide cohort of transcription factors located
in cell nucleus. The osteogenic effects of
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BMP-2 are mediated by formation of Runx2–
Smad complexes (Hassan et al. 2006). Smads,
the TGF-b intracellular proteins, form regula-
tory complexes with the transcription factors
to regulate the downstream phenotypic target
genes induction. BMP-2 promotes the osteo-
blast maturation by increasing the upregula-
tion expression of series of transcription
factors in cell nucleus (RUNX2, OSX, DLX5),
which then lead to the expression of OSE2,
the osteoblast marker gene that is responsible
for the osteoblast differentiation (Komori
et al. 1997).
BMPs activity was first identified when
demineralized bone matrix-induced pre-
osteoprogenitor cells to differentiate into
osteoblasts and facilitate new bone forma-
tion when implanted in extraskeletal sites
(Urist 1965). The biologic and cellular func-
tions of BMPs were later discovered through
in vitro and in vivo studies. In addition to
ectopic bone and cartilage development and
regeneration process (Sporn & Vilcek 1996),
BMPs are also involved in numbers of non-
osteogenic development process: BMPs play
critical roles in heart and neural develop-
ment. This group of growth factors are
involved in the differentiation of epidermal,
adrenergic phenotype in developing neurons,
chondrocyte, and osteoblast precursors (Chen
et al. 2004).
Since the discovery of BMP’s osteoinduc-
tive ability, much of the research focus has
been on the therapeutic application of speci-
fic BMP isoforms in regenerative therapy. In
recent preclinical and human studies, the
use of BMP-2, 4, 6, 7, 9, and 14 showed
promising osteoinduction in repairing radial,
femoral, spinal fusion, and cranial bone
defects (Sigurdsson et al. 1997; Govender
et al. 2002; Dai et al. 2005; Stavropoulos
et al. 2011; Even et al. 2012; Carreira et al.
2014). Based on radiographic, histological,
and mechanical evaluation, the osseous
defects resulted in successful healing of seg-
mental defects. In sight of the commonality
of dentoalveolar defects, Bowers integrated
BMP-2 into periodontal grafting material and
successfully regenerated significant amount
of periodontal attachment apparatus includ-
ing new cementum, connective tissue, and
new bone (Bowers et al. 1991). Some studies
had also shown successful application of
BMP-2 in repairing peri-implant defects and
induce implant osteointegration (Sigurdsson
et al. 1997). However, the use of BMPs in
clinical setting tends to be restricted due to
the technique sensitive protein extraction
procedure and low product yield. With the
aid of DNA recombinant bioengineering
technology, more than 20 types of BMPs
have been cloned and characterized (Even
et al. 2012). Further, recombinant human
BMP-2 (rhBMP-2) has been made readily
available for therapeutic use given its rapid
ability to trigger the differentiation of osteo-
blasts.
Loss of crestal alveolar bone and increased
maxillary sinus pneumatization are common
clinical sequelae afflicting the edentulous
posterior maxilla (Sharan & Madjar 2008).
Surgical approaches such as total or segmen-
tal bone onlays, interpositional bone graft,
and grafting of the maxillary sinus were
developed to incorporate the use of different
types of bone graft material for sinus floor
augmentation (Chiapasco et al. 2009).
Although autogenous bone has been consid-
ered as the gold standard for augmentation
procedures based on the high success rate
(Esposito et al. 2009), it has limited avail-
ability and may require another surgical
area as donor site. Studies with animal
models have demonstrated the high osteo-
genic activity of rhBMP-2; rhBMP-2 seemed
to produce similar bone apposition results
as autogenous bone (Wada et al. 2001; Lee
et al. 2013). Additionally, a human study
further demonstrated that the administra-
tion of rhBMP-2 via impregnated on absorb-
able collagen sponge (ACS) in a 2-stage
maxillary sinus floor procedure induced de
novo bone growth (Boyne et al. 1997). In
the study, new bone growth was observed
in 100% of the 11 evaluated patients with
histology evidence of normal remodeling
and maturation activity in the rhBMP-2-
induced bone. However, to further warrant
the clinical and histometric outcomes of
introducing rhBMP-2 in maxillary sinus
floor augmentation procedures, a critical
systematic review will be needed. Hence,
this study aims to investigate the effect of
the rhBMP-2 on sinus volumetric and histo-
metric changes after sinus floor augmenta-
tion compared with the conventional
approach, which is the use of bone grafting
materials without additional biologics or
growth factors.
Materials and methods
Patient, intervention, comparison, outcome
(PICO) question
P: Healthy patients receiving sinus floor aug-
mentation procedures.
I: Human clinical trials with data on sinus
volumetric and/or histometric outcomes in
sinus grafting procedures, with ≥10 augmen-
tation sites in each study group, and with a
follow-up period of at least 6 months.
C: The effect of rhBMP-2 on sinus
volumetric and histometric changes after
sinus floor augmentation compared with the
use of bone grafting materials without an
addition of biologic agents.
O: Risk ratio of implant survival rates (SR)
and weighted mean difference (WMD) of ver-
tical bone level (VBL) gain, bone density, and
histometric outcomes.
Fig. 1. Mechanism of BMP-2 and the intracellular signaling pathway. Smad: Small mothers against decapentaplegic;
BMPR: BMP receptor; RUNX2: runt-related transcription factor 2; OSX: osterix; DLX5: distal-less homeobox 5 gene;
OSE2: osteoblast-specific cis-acting element 2; P: phosphorylated.
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Search strategy
A search of 4 electronic databases, including
PubMed/MEDLINE, EMBASE, Web of
Science, and Cochrane Central, for relevant
studies published in the English language
from January 1990 until February 2015 was
performed. The search terms used, where mh
represented the MeSH terms and tiab
represented title and/or abstract, were as fol-
lows: (“growth substances”[mh] OR “growth
factor”[tiab] OR “biologic factors”[mh] OR
“biologic agent”[tiab] OR “biologics”[tiab] OR
“bone morphogenetic proteins”[mh] OR
“BMP”[tiab] OR “rhBMP-2”[tiab]) AND (“den-
tal implants”[mh] OR “maxillary sinus”[mh]
OR “sinus floor augmentation”[mh] OR
“maxillary sinus augmentation”[tiab] OR “si-
nus floor elevation”[tiab] OR “sinus augmen-
tation”[tiab] OR “sinus elevation”[tiab] OR
“sinus lift”[tiab] OR “sinus lifting”[tiab]).
A hand search was also carried out in den-
tal and implant-related journals from January
2000 to February 2015, including Journal of
Clinical Periodontology, Journal of Periodon-
tology, Clinical Implant Dentistry and
Related Research, International Journal of
Oral and Maxillofacial Implants, Clinical
Oral Implants Research, Implant Dentistry,
International Journal of Oral and Maxillofa-
cial Surgery, Journal of Oral and Maxillofa-
cial Surgery, Journal of Dental Research,
Journal of Prosthetic Dentistry, International
Journal of Prosthodontics, Journal of Oral
Implantology, and International Journal of
Periodontics and Restorative Dentistry.
European Journal of Oral Implantology was
searched from Winter 2008 to Winter 2014
issues. Furthermore, a search in the refer-
ences of included papers was conducted for
publications that were not electronically
identified. The search strategy was performed
by one examiner (G-HL).
Studies were selected if they fulfilled the
following inclusion criteria: human clinical
trials, with data on comparison of sinus volu-
metric and/or histometric outcomes with and
without the use of rhBMP-2 in sinus grafting
procedures, with ≥10 augmentation sites in
each study group, and with a follow-up
period of at least 6 months. Patient-centered
outcome, if there is any, was also recorded.
Reviews and case reports were excluded, but
the bibliographies of these studies were
screened for potential articles to be included.
Potential articles were examined in full text
by two reviewers (G-HL and GL), and their
eligibility for this review was confirmed after
discussion. The level of agreement between
the reviewers regarding study inclusion was
calculated using kappa statistics.
Risk of bias assessment
The criteria used to assess the quality of the
selected randomized control trials (RCTs)
were modified from the randomized clinical
trial checklist of the Cochrane Center (Hig-
gins & Green 2011) and the CONSORT state-
ment (Schulz et al. 2010), which provided
guidelines for the following parameters:
sequence generation, allocation concealment
method, masking of the examiner, address of
incomplete outcome data, and free of selec-
tive outcome reporting. The degree of bias
was categorized as: low risk if all the criteria
were met, moderate risk when only one crite-
rion was missing, and high risk if two or
more criteria were missing. Two reviewers
(G-HL and GL) assessed all the included
articles independently.
Data extraction
Data were extracted by two observers (G-HL
and GL) independently from the papers that
met the inclusion criteria. If any disagree-
ment was found, another reviewer was con-
sulted (H-LC). Demographic information was
recorded for each study, including the study
design, sample size, individual characteris-
tics, numbers of augmented sites, techniques
used, doses of rhBMPs-2, types of grafting
materials, and follow-up period.
Additional variables, if there were any,
recorded for each study were VBL gain, SR,
bone density, and percentage of vital bone
and residual grafting materials. If necessary,
authors of the potentially qualified papers
were contacted for more detailed data.
Data analyses
The primary outcome was VBL gain, with SR,
bone density, and histometric parameters as
the secondary outcomes. The risk ratio of SR
and the pooled WMD of VBL, bone density,
percentage of newly formed vital bone, and
percentage of residual grafting materials were
estimated using a computer program (RevMan
version 5.0, The Nordic Cochrane Centre, The
Cochrane Collaboration, Copenhagen, 2008).
The contribution of each article was weighed.
For studies with more than one treatment
arm, the results from all arms were combined
together. Random-effects meta-analyses of the
selected studies were applied to minimize any
bias caused by methodological differences
among studies. Forest plots were generated to
graphically represent the difference in primary
and secondary outcomes for all included stud-
ies using augmented sites as the analysis unit.
A P value = 0.05 was used as the level of sig-
nificance. Heterogeneity was assessed with
chi-square test and I2 test, which ranges
between 0% and 100% and lower values repre-
sent less heterogeneity. In addition, the funnel
plots were used to assess the presence of the
publication bias. The reporting of these meta-
analyses adhered to the PRISMA (Preferred
Reporting Items for Systematic Review and
Meta-Analyses, Fig. 2) statement (Liberati
et al. 2009).
Results
The screening process was shown in Fig. 2.
Electronic and hand searches yielded 815 arti-
cles, of which 14 articles were selected for
full-text evaluation after screening their titles
and abstracts. Eight articles (Boyne et al.
1997; Serra et al. 2006; Tarnow et al. 2010;
Jensen et al. 2012, 2013, 2014; Jensen &
Adams 2014; Luiz et al. 2014) were further
excluded; the reasons for exclusion were
listed in Table 1. Six articles (Boyne et al.
2005; Triplett et al. 2009; Kao et al. 2012;
Froum et al. 2013b, 2014; Kim et al. 2014)
were included in this systematic review. The
main features and conclusions of the
included studies were summarized in
Table 2. An additional study (Kim et al.
2015) was identified during the revision of
the current review. The data of this study
were listed in Table 2 but not pooled in the
meta-analyses due to disqualification of
selection process.
The kappa value for inter-reviewer agree-
ment for potentially relevant articles was
0.93 (titles and abstracts) and 1 (full-text arti-
cles), indicating an “almost perfect” agree-
ment between the two reviewers (Landis &
Koch 1977).
Features of the included studies
Study design and patient features
Six RCTs (Boyne et al. 2005; Triplett et al.
2009; Kao et al. 2012; Froum et al. 2013b,
2014; Kim et al. 2014) were included. Most
studies reported the age range and the gender
of the study participants except for two stud-
ies (Froum et al. 2013b, 2014). In addition, all
Table 1. Summary of the excluded articles
Reason for exclusion Authors/Year
No data reported
for analysis
Serra et al. (2006)
Not randomized
clinical trials
Boyne et al. (1997)
Tarnow et al. (2010)
Jensen et al. (2012)
Jensen et al. (2013)
Jensen & Adams (2014)
Jensen et al. (2014)
Luiz et al. (2014)
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studies performed computed tomography
(CT) scan within 4- to 9-month period after
sinus floor augmentation to evaluate the vol-
umetric changes. Two included studies
(Boyne et al. 2005; Triplett et al. 2009)
reported the SR of the implants; other studies
did not report this information.
Dose of rhBMP-2 and types of grafting materials
Two different types of rhBMP-2 were intro-
duced. Five studies (Boyne et al. 2005; Tri-
plett et al. 2009; Kao et al. 2012; Froum et al.
2013b, 2014) used rhBMP-2 derived from
mammalian cells, and one study (Kim et al.
2014) used Escherichia coli-produced rhBMP-
2 (ErhBMP-2). Regarding the grafting materi-
als, two studies (Boyne et al. 2005; Triplett
et al. 2009) introduced rhBMP-2 with ACS
(rhBMP-2/ACS) to augment maxillary sinuses
as experimental group and autogenous graft
in combination with allogenous graft as con-
trol group. Another two (Froum et al. 2013b,
2014) studies used rhBMP-2/ACS mixed with
mineralized cancellous bone allograft
(MCBA) as test group and MCBA alone as
control. One study (Kao et al. 2012) used
rhBMP-2/ACS mixed with deproteinized
bovine bone as test group and deproteinized
bovine bone alone as control group. Another
one study (Kim et al. 2014) used hydroxyap-
atite and beta-tricalcium phosphate (BCP) at
a ratio of 30:70 as the carrier of ErhBMP-2
solution in test group and BCP alone as
control group. All the studies used rhBMP-2
of 1.50 mg/ml concentration for sinus floor
augmentation; however, three studies
(Boyne et al. 2005; Froum et al. 2013b, 2014)
introduced an additional experimental arm
to test the efficacy of 0.75 mg/ml
concentration.
Risk of bias assessment
The results of risk of bias assessment for
included RCTs were summarized in Table 3.
Three studies were considered to have a
moderate risk of bias and another 3 studies
were considered to have a high risk of bias.
The results of funnel plots were reported as
Supplementary Figs S1–S5 for evaluating the
potential publication bias. However, the fun-
nel plots should be interpreted with caution
because the mixture of various study designs
as well as limited number of studies
included.
Results of the meta-analyses for VBL gain
Four studies (Boyne et al. 2005; Triplett et al.
2009; Kao et al. 2012; Froum et al. 2014)
reported the data on VBL gain. The weighted
mean bone gain was 10.17  0.54 mm in
rhBMP-2 group and 10.50  0.68 mm in con-
trol group. The WMD of VBL gain was
0.14 mm (95% CI = 1.91–1.62 mm,
P = 0.87, Fig. 3). No statistically significant
difference was detected between groups. A
high degree of heterogeneity (I2 = 70% and P
value for chi-square test was 0.02) among
selected studies was noticed.
Results of SR
Of the included studies, only two studies
reported SR. One study (Boyne et al. 2005)
reported 79%, 88%, and 81% implant SR at
grafted sites with the use of 1.5 mg/ml
rhBMP-2, 0.75 mg/ml rhBMP-2, and without
the use of rhBMP-2, respectively. Another
study (Triplett et al. 2009) reported 87% SR
for both test and control groups after
6 months of implant placement. Meta-
analysis for the comparison of SR among
selected studies presented an overall risk
ratio of 1.00 (95% CI = 0.94–1.07), and no
statistical significance (P = 0.94) was found
(Fig. 4) between groups treated with rhBMP-2
and treated with conventional approach. The
comparisons presented a low (P value for chi-
square test = 0.59 and I2 test = 0%) degree of
heterogeneity between two studies.
Results of the meta-analyses for bone density
Three studies (Boyne et al. 2005; Triplett
et al. 2009; Froum et al. 2014) reported data
on bone density after sinus floor augmenta-
tion by measuring the CT scan images.
Two studies (Boyne et al. 2005; Triplett
et al. 2009) reported the newly formed bone
density using mineral density unit at 4–
6 month after augmentation. However, one
(Triplett et al. 2009) of the studies did not
report the standard deviation of the reported
data, resulting in the exclusion of this
study when meta-analyzing. Another study
(Froum et al. 2014) reported the bone den-
sity in Hounsfield units based on CT scans
taken at 6- to 9-month follow-up. The
Hounsfield units were subsequently cali-
brated and reported as mineral density in
the current study based on an equation pro-
posed from a previous study (Schileo et al.
2008). The WMD of bone density was
142.42 mg/cm3 (95% CI = 310.62–
25.78 mg/cm3, P = 0.10, Fig. 5). Although
no statistically significant difference was
detected between groups, a trend of favoring
control group with higher newly formed
bone density was noted. A high degree of
heterogeneity (I2 = 82% and P value for chi-
square test was 0.02) between selected stud-
ies was noticed.
Results of the meta-analyses for the
histometric outcomes
Three studies (Kao et al. 2012; Froum et al.
2013b; Kim et al. 2014) reported the data on
percentages of vital bone and residual grafting
materials based on the examination of the
core samples, retrieved 6–9 months after
sinus floor augmentation. Interestingly,
among these three studies, one study used
allograft (MCBA), another one used xenograft
(deproteinized bovine bone), and the other
one used alloplastic material (BCP) as the
carriers for rhBMP-2. The weighted mean per-
centage of vital bone was 18.21  3.56% in
rhBMP-2 group and 22.69  2.63% in control
group. The WMD of the percentage of vital
bone was 4.59% (95% CI = 11.73–2.56%,
P = 0.21, Fig. 6). No statistically significant
difference was detected between groups. A
moderate degree of heterogeneity (I2 = 37%
and P value for chi-square test was 0.20)
Table 3. Risk assessment of publication bias for the included RCTs













Sequence generation Yes Yes Yes Yes Yes Yes
Randomization methods RCT RCT RCT RCT RCT RCT
Allocation concealment method Yes Yes Yes Yes Yes Yes
Examiner masked Yes ? ? Yes Yes No
All patients accounted for at end of study No No No No No No
Incomplete outcome data adequately addressed Yes Yes NA NA NA NA
Free of suggestion of selective outcome reporting Yes Yes Yes Yes Yes Yes
Estimated potential risk of bias Moderate High High Moderate Moderate High
NA, Not applicable; ?, Not reported.
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Fig. 2. PRISMA flow chart illustrates the publication selection process.
Fig. 3. Meta-analysis for the comparison of VBL gain among selected studies. The WMD of VBL gain was 0.14 mm (95% CI = 1.91–1.62 mm, P = 0.87). No statistically sig-
nificant difference was detected between groups. A high degree of heterogeneity (I2 = 70% and P value for chi-square test was 0.02) among selected studies was noticed.
Fig. 4. Meta-analysis for the comparison of SR among selected studies presented an overall risk ratio of 1.00 (95% CI = 0.94–1.07), and no statistical significance (P = 0.94) was
found. The comparisons presented a low (P value for chi-square test = 0.59 and I2 test = 0%) degree of heterogeneity between two studies.
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among selected studies was noticed. Simi-
larly, the WMD of the percentage of residual
bone grafting materials was 9.90% (95%
CI = 26.38–6.58%, P = 0.21, Fig. 7). No sta-
tistically significant difference was detected
between groups. A high degree of heterogene-
ity (I2 = 93% and P value for chi-square test
was < 0.0001) among selected studies was
presented.
Interestingly, a multicenter study (Kim
et al. 2015) reporting histometric outcomes
was identified during the revision of the cur-
rent review. However, even the data of this
article were pooled, no statistically signifi-
cant difference could be detected for percent-
ages of vital bone (WMD = 0.32% with 95%
CI = 9.99–10.63%, P = 0.95) and residual
grafting materials (WMD = 8.35% with
95% CI = 20.38–3.69%, P = 0.17) between
groups (Figures not shown).
Analysis based on the results of heterogeneity
test
Of all the investigated variables, the meta-
analyses presented moderate-to-high degree
of heterogeneity among the studies except for
SR. Several confounding factors, including
various interventions, types of rhBMP-2,
potential risks of bias, and follow-up period,
might contribute to the moderate-to-high
degree of heterogeneity. The heterogeneity
could also result from combining the data of
two treatment arms (1.50 mg/ml rhBMP-2
and 0.75 mg/ml rhBMP-2) to represent the
outcomes of the test group in 3 studies
(Boyne et al. 2005; Froum et al. 2013b, 2014).
As a result, the authors have performed the
analyses to compare the data with the use of
1.50 mg/ml rhBMP-2 only to the control
group (data with the use of 0.75 mg/ml were
not pooled), but all the comparisons still did
not reach statistically significant difference
between test and control groups. In addition,
the same degree of the heterogeneity (low,
moderate, or high) was found among the
selected studies for any of the investigated
variables.
When moderate-to-high degree of hetero-
geneity is present, a subgroup analysis or
regression analysis is usually the recom-
mended statistic method; however, these anal-
yses were precluded in the current review due
to the limited number of the included studies.
Therefore, the results of the meta-analyses
should be interpreted with caution.
Discussion
The results of current review demonstrated
that the use of rhBMP-2 in human maxillary
Fig. 5. Meta-analysis for the comparison of bone density among selected studies. The WMD of bone density was 142.42 mg/cm3 (95% CI = 310.62–25.78 mg/cm3, P = 0.10).
Although no statistically significant difference was detected between groups, a trend of favoring control group with higher newly formed bone density was noted. A high degree
of heterogeneity (I2 = 82% and P value for chi-square test was 0.02) between selected studies was noticed.
Fig. 6. Meta-analysis for the comparison of the percentage of vital bone formation among selected studies. The WMD of the percentage of vital bone was 4.59% (95%
CI = 11.73–2.56%, P = 0.21). No statistically significant difference was detected between groups. A moderate degree of heterogeneity (I2 = 37% and P value for chi-square test
was 0.20) among selected studies was noticed.
Fig. 7. Meta-analysis for the comparison of the percentage of residual bone graft particles among selected studies. The WMD of the percentage of residual bone grafting materi-
als was 9.90% (95% CI = 26.38–6.58%, P = 0.21). No statistically significant difference was detected between groups. A high degree of heterogeneity (I2 = 93% and P value
for chi-square test was < 0.0001) among selected studies was detected.
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sinus floor augmentation did not show signif-
icant difference on dimensional nor histo-
metric outcomes after 6–9 months of healing
period in comparison with conventional sur-
gical procedures. Similar results were previ-
ously reported in a systematic review
published by de Freitas et al. (2015). In the
study, the authors reported sinus floor aug-
mentation following autogenous bone graft
was significantly greater than the rhBMP-2/
ACS group in terms of VBL gain. Even
though the present review included more ran-
domized controlled trials, similar results
were found regarding the dimensional change
between groups. In addition, the current
review evaluated the amount of vital bone
formed after 6–9 months of the sinus floor
augmentation procedure by analyzing previ-
ously published histomorphometric data. No
significant difference was detected regarding
the percentages of vital bone formation and
residual bone grafting materials. This implies
that in maxillary sinus floor augmentation,
rhBMP-2 achieved similar histometric out-
comes when compared to conventional sinus
grafting procedure. However, it is worth not-
ing this finding is only based on 3 studies
(Kao et al. 2012; Froum et al. 2013b; Kim
et al. 2014) and with only 6- to 9-month
follow-up. Among these three studies, one
study used MCBA (Froum et al. 2013b),
another one used xenograft (Kao et al. 2012),
and the other one used BCP (Kim et al. 2014)
as the carriers for rhBMP-2. More interest-
ingly, although meta-analysis did not detect
any significant difference in percentage of
vital bone formation, Kao et al. reported that
new bone formation was compromised when
a deproteinized bovine bone was used as a
carrier.
Sinus floor augmentation with the use of
rhBMP-2 has been widely investigated in ani-
mal studies (Nevins et al. 1996; Hanisch
et al. 1997) and was subsequently introduced
in human studies. In 1997, Boyne et al.
(1997) published the first article using
rhBMP-2/ACS in human maxillary sinus
grafting procedures and reported a gain of
8.51 mm at 4-month follow-up. This result
may appear as optimal and clinically applica-
ble; however, after examining the data clo-
sely, the bone height gain actually ranged
from 2.28 mm to 15.73 mm, and only 45%
of the participants met the ideal criteria for
dental implant placement. On the contrary,
the histological evidence had identified mod-
erate to large number of osteoblasts and cap-
illaries present in the newly induced bone,
which suggesting the benefits of introducing
rhBMP-2 to the sinus procedures given its
osteoinductive property. Perhaps, the true
benefit of using rhBMP-2 in this procedure
might not reflect on directly gaining bone
volume, but rather in the new bone induc-
tion potential. Several clinical studies (Moon
et al. 2011; Riben & Thor 2012) had shown
that with a good ability of space mainte-
nance, the optimal volumetric gain could be
achieved even with the absence of bone graft-
ing materials or biologic agents. Thus, clini-
cians should not expect significant gain of
bone height when applying rhBMP-2 in sinus
procedures; in contrast, a stable maintenance
of the elevated space is the determinant for
gaining vertical bone height.
Regarding the implant SR after using
rhBMP-2 in sinus floor augmentation proce-
dures, only 2 articles (Boyne et al. 2005; Tri-
plett et al. 2009) were pooled and the meta-
analysis did not detect a difference between
the experimental and control groups (overall
risk ratio of 1.00, 95% CI = 0.94–1.07,
P = 0.94). Interestingly, both studies reported
that the majority of implant failures occurred
before prosthetic loading and resulted from
inadequate bone quality during the osseointe-
gration phase. Therefore, a possible longer
healing period (>6 months) might be neces-
sary before implant placement to achieve bet-
ter bone quality. Future clinical trials should
be performed to determine the ideal healing
time and surgical protocol when using
rhBMP-2/ACS to augment sinus floor.
Cone beam CT scans have been commonly
used to determine bone width and height of
the alveolar ridge. Although it is not very fre-
quent, these scans have also been used to
measure bone density (Aranyarachkul et al.
2005). In the current study, meta-analysis
failed to detect difference between treatment
and control groups in regard of regenerated
bone density after 6 months of healing; how-
ever, there was a tendency that control group
demonstrated better bone density than the
rhBMP-2 group. Interestingly, one study (Tri-
plett et al. 2009) reported a significant higher
bone density in the bone graft group com-
pared with the rhBMP-2/ACS treatment
group at 6 months postoperatively. However,
the induced bone density in the rhBMP-2/
ACS group was significantly higher than the
bone graft group at 6 months after functional
loading. The authors concluded that the bone
density around implants after functional
loading in augmented sinus with rhBMP-2/
ACS performed as well as that of the bone
graft group. Furthermore, it should be noted
that a higher density of mineralized tissue
shown in CT scan/radiograph at early stage
of healing does not necessarily equate to
higher amount of mature bone because the
radiopaque/mineral property of the grafting
materials might contribute to overestimation
of bone quality. In two studies (Boyne et al.
2005; Triplett et al. 2009), the experimental
group had no mineralized materials grafted
into the sinus; another study (Froum et al.
2014) grafted a relatively smaller amount of
allograft into the sinus in the treatment
group while a larger amount of allograft used
for the control. Therefore, special precaution
should be taken when interpreting the results
of this parameter.
Compared to the bone density measure-
ment, the histomorphometric analysis of the
core specimens provides more detailed infor-
mation regarding the percentage of newly
formed vital bone as well as residual bone
particles. In a previous study, Kao et al.
(2012) reported negative effect on bone forma-
tion when using rhBMP-2 in combination
with deproteinized bovine bone in maxillary
sinus floor augmentation. They speculated
that the upregulation of receptor activator of
nuclear factor kappa-B ligand might be
responsible for this phenomenon. However,
the current review failed to detect the differ-
ence between the treatment and control
groups in terms of histometric comparisons.
These outcomes were in accordance with
several recent studies (Froum et al. 2013b;
Kim et al. 2014). Interestingly, recent human
study (Kim et al. 2015) and animal trials
(Ono et al. 2014; Yon et al. 2015) had shown
promising results of significant bone forma-
tion and enhanced osteointegration with the
use of BMP-2. This inconsistency between
human and animal studies could be
explained with the early release and influ-
ence of the BMP-2 on bone formation. As
most of the human studies retrieved the core
specimens at the time of the implant place-
ment (6–9 months after sinus floor augmen-
tation), meanwhile, the bone grafting
materials used in the control groups could
potentially already turn over into native
bone, resulting in histologically similar pat-
terns with the treatment specimens. Yon
et al. (2015) had shown that BMP-2 was
released from the carrier over the first 3 days
in vitro and maintained at a reduced level
through day 21 and significantly enhanced
local bone formation. Kim et al. (2015) also
reported low-dose ErhBMP-2 significantly
enhanced vital bone formation in early
stages (3 months) of healing. Therefore,
the effect of the use of rhBMP-2 in sinus
floor augmentation on vital bone formation
might be attained at the very early stage of
the healing period, but this difference
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possibly will diminish after 6–9 months post-
operation.
Two of the included articles (Froum et al.
2013b; Kim et al. 2014) reported the differ-
ence of percentage of vital bone formation
between the sites with perforated and non-
perforated sinus membranes. Froum et al.
(2013b) reported that more bone formation
(22.37%) in perforated sinuses was associated
with higher dosage of rhBMP-2/ACS. In con-
trast, Kim et al. (2014) showed less bone for-
mation in perforated sinuses with the
treatment of BMPs. The authors speculated
that the perforated Schneiderian membrane
might compromise the osteoinductive capac-
ity of rhBMP-2. One published clinical trial
(Froum et al. 2013a) demonstrated that perfo-
rated membranes did not appear to be an
adverse complication in terms of vital bone
formation or implant survival if properly
repaired. However, rhBMP-2 was not intro-
duced in that particular study thus the con-
clusion might not be applicable. The effect of
membrane perforation on vital bone forma-
tion in maxillary sinus floor augmentation
with the use of rhBMP-2 remains unclear at
this time.
Although the current study did not show
a significant difference between the rhBMP-
2 group and control group, there is a lack
of human clinical trials to investigate
potential indications, such as limited resid-
ual bone height or long span grafted area,
of the use of rhBMP-2 in sinus floor aug-
mentation procedures. The residual bone
height between bone crest and sinus floor
has been associated with long-term implant
success and prognosis (Pjetursson et al.
2009; Del Fabbro et al. 2012). A previous
study concluded that a more favorable prog-
nosis for sinus floor augmentation proce-
dure was noted when residual ridge height
was at least 5 mm (Del Fabbro et al. 2012).
In addition, recent studies also showed that
a higher implant SR was associated with a
higher initial bone height (Pjetursson et al.
2009; Soardi et al. 2013). In this case, a use
of biologic agents such as BMP-2 might
potentially enhance positive surgical out-
comes due to its angiogenesis and osteogen-
esis characteristics. More human clinical
trials are encouraged to investigate this
clinically relevant topic.
Serious complications such as swelling or
infection might occur after the use of
rhBMP-2 in oral and maxillofacial proce-
dures. Minor complications have been also
reported, including post-operation bleeding
and pain (Kim et al. 2014). In 2012, Woo
(2012) reported that local edema, erythema,
and pain were the most frequent post-opera-
tion complications after the use of rhBMP-2.
In the present review, two studies (Boyne
et al. 2005; Triplett et al. 2009) reported the
use of autogenous bone had a significantly
greater incidence of oral edema, ecchymosis,
pain, arthralgia, abnormal gait, sinusitis,
skin rash, and erythema than the rhBMP-2/
ACS group, indicating the morbidity associ-
ated with bone graft harvesting. However,
higher percentage (82%) of the patients
in rhBMP-2/ACS group experienced facial
edema than autograft group (38%, Boyne
et al. 2005). The post-operation facial edema
might result from an influx of fluid and cells
into the treatment site (Triplett et al. 2009)
during the initial phase of the wound heal-
ing. Anti-inflammatory medications could be
prescribed to subside these symptoms (Tan
et al. 2013).
Although the cost-effectiveness of BMP use
in spinal fusion procedures has been reported
(Ackerman et al. 2002; Cahill et al. 2009),
this topic has not yet been widely discussed
in dental field. Based on the results of the
current study, an additional benefit with the
use of rhBMP-2 in sinus floor augmentation
procedures could not be warranted. However,
rhBMP-2 might be used as an alternative to
autogenous or allogenous graft. Therefore,
clinicians should weigh potential benefits
and downsides of applying this biologic agent
in their patients. Future studies need to be
conducted to combine analysis of patient-
centered outcomes, procedure morbidity, and
time for graft harvest as factors that may
have an influence on assessing cost-effective-
ness.
Several limitations of the current review
are presented. First, the number of the
included papers is low (N = 6). Second, there
are various degrees of heterogeneity and pub-
lication bias. Heterogeneity is related to the
presence of confounding factors within and
among the selected studies, for example, dif-
ferent study designs, follow-up periods, types
and concentrations of rhBMP-2, and grafting
materials used. Although the current study
clustered rhBMP-2 as a single intervention,
there might be potential difference and effect
when different formulations/concentrations
of rhBMP-2 are used. Furthermore, most of
the analyses presented a moderate to large
heterogeneity among included studies; there-
fore, cautious interpretation of the data is
needed. Third, the study results might be
influenced by the potential confounding fac-
tors, such as residual bone height and
patients’ health history. However, none of
the included study adjusted for the related
confounding factors. Fourth, volumetric
changes and bone density were measured in
3-dimension, and different settings and
brands of CT scan machine might have an
influence on the reported outcomes. Fifth,
owing to the limited comparable data,
patient-centered outcomes were not statisti-
cally analyzed in the current review. Sixth,
current review only included studies written
in English, which could introduce a selection
bias.
Conclusions
This systematic review revealed that the use
of rhBMP-2 in maxillary sinus floor augmen-
tation achieved similar clinical and histomet-
ric outcomes when compared to conventional
sinus grafting procedures after a healing per-
iod of 6–9 months. However, previous studies
showed the morbidity and other patient-
reported outcomes were improved in rhBMP-
2 approaches as compared to bone autograft
procedures (both intraoral and extraoral bone
harvesting due to donor site morbidity).
Long-term studies are required to determine
the cost-benefit of sinus floor augmentation
procedures for patients requiring implant
reconstruction.
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